Artios Raises 115M for DDR Trials, Microclots Reveal Long COVID Clues, Genetic Key Alters Seasonal Mammal Behavior, Star Beyond Solar System Ejects CME, and more...
Update: 2025-11-17
Description
(0:10 ): Artios Pharma Raises $115M to Boost DDR Cancer Pipeline with Promising New Trials
(2:15 ): Study Reveals Microclots and NETs as Key Biomarkers for Diagnosing Long COVID
(4:01 ): Breakthrough: Genetic Key to Seasonal Behavior in Mammals Unlocked by New Study
(5:47 ): First Ever Coronal Mass Ejection Detected from Star Beyond Solar System, Impacts Exoplanet Habitability
(7:32 ): BioRestorative's BRTX-100 Gains FDA Fast Track: Aims for Accelerated Phase 3 Trial for Back Pain Therapy
To subscribe visit https://www.brief.news.
For more updates in your inbox each morning visit www.brief.news.
Image credit: COINTURK FINANCE
(2:15 ): Study Reveals Microclots and NETs as Key Biomarkers for Diagnosing Long COVID
(4:01 ): Breakthrough: Genetic Key to Seasonal Behavior in Mammals Unlocked by New Study
(5:47 ): First Ever Coronal Mass Ejection Detected from Star Beyond Solar System, Impacts Exoplanet Habitability
(7:32 ): BioRestorative's BRTX-100 Gains FDA Fast Track: Aims for Accelerated Phase 3 Trial for Back Pain Therapy
To subscribe visit https://www.brief.news.
For more updates in your inbox each morning visit www.brief.news.
Image credit: COINTURK FINANCE
Comments
In Channel






















